• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Novel Oral Anticoagulants in Peripheral Artery Disease. Current Evidence.
CONCLUSION: For the time being, novel oral anticoagulants in combination with aspirin may provide an alternative treatment in PAD, however, it is deemed necessary to identify patient subgroups who will benefit the most. PMID: 30585539 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - December 26, 2018 Category: Drugs & Pharmacology Authors: Koutsoumpelis A, Argyriou C, Tasopoulou KM, Georgakarakos EI, Georgiadis GS Tags: Curr Pharm Des Source Type: research

Oral antiplatelet and anticoagulant agents in the prevention and management of ischemic stroke.
Abstract Despite numerous advances over the last 50 years, stroke continues to be a leading cause of death and disability worldwide. The treatment and prevention of stroke has undergone extensive study, and significant advances in medical management have occurred within the past decade principally with the development of new classes of orally active anticoagulant drugs. Here we review these recent breakthroughs and the varying roles of anticoagulants and antiplatelet agents in the prevention and management of different ischemic stroke subtypes, as well as describe the benefits and ongoing challenges to incorporati...
Source: Current Pharmaceutical Design - December 20, 2016 Category: Drugs & Pharmacology Authors: Shrestha S, Coy S, Bekelis K Tags: Curr Pharm Des Source Type: research

Anticoagulant prevention in patients with atrial fibrillation: alternatives to vitamin K antagonists.
Abstract Patients with nonvalvular atrial fibrillation (AF) and risk factors for stroke need anticoagulation to avoid thromboembolic complications. Vitamin K antagonists (VKAs) are an established pharmacological group the use of which is recommended by guidelines. However, VKAs (like warfarin) have major disadvantages, such as a variable dose-effect relationship, drug and food interactions, the need for regular blood testing and dose titration, and, finally, a substantial risk of bleeding. New oral anticoagulants are intended to replace warfarin, being at least as safe and effective, and lacking some of the disadv...
Source: Current Pharmaceutical Design - December 26, 2012 Category: Drugs & Pharmacology Authors: Kozlowski D, Budrejko S, Raczak G, Rysz J, Banach M Tags: Curr Pharm Des Source Type: research

Clopidogrel, Aspirin and Proton Pump Inhibition after Percutaneous Valve Implants: An Update.
Conclusions: TAVR is a new technology that compresses a tissue valve onto an expandable stent. Technical and procedural issues have been solved, but strokes and major bleeding still affect patients' life despite double antiplatelet therapy given to reduce MACCE. To balance pros and cons, antithrombotic therapy with Warfarin or new anticoagulants can be used in patients with previous AF or NOAF to prevent stroke; while single antiplatelet with PPI is a better alternative in patients with liver disease, gastric ulcer or drug abuse to avoid bleeding events. While waiting for randomized trials, a tailored therapy based upon ph...
Source: Current Pharmaceutical Design - December 4, 2012 Category: Drugs & Pharmacology Authors: Fusari M Tags: Curr Pharm Des Source Type: research